Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are a class of
antidiabetic drugs developed over the past 15 years. GLP-1, a gastrointestinal peptide …

Introduction The present study aimed to evaluate the effects of glucagon-like peptide 1
receptor agonists (GLP-1RAs) on clinical and safety outcomes including glycemic control …

Glucagon-like peptide-1 (GLP-1) has been evaluated for use in the treatment of type 2
diabetes mellitus (T2DM) due to its role in glucose regulation. Four GLP-1 receptor agonists …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are commonly used in combination
with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable
glucose-lowering medications approved for the treatment of adult patients with type 2 …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …

The incretin system has become an important target in the treatment of type 2 diabetes in
recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose …

Glucagon-like peptide-1 receptor agonists (also known as GLP-1 receptor agonists, GLP-
1DAs, incretin mimetics, or GLP-1 analogs)) are a class of medications utilized in the …

Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes
mellitus (T2DM) and glucose regulation has led to innovative research and new treatment …